Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1973 1
1974 1
1975 2
1980 2
1981 2
1982 1
1985 3
1990 1
1992 1
2003 1
2005 1
2006 1
2007 1
2009 1
2010 2
2011 1
2012 1
2014 3
2015 2
2016 2
2017 2
2018 1
2019 1
2020 2
2021 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Stein EM, et al. Among authors: franovic a. Blood. 2021 Apr 1;137(13):1792-1803. doi: 10.1182/blood.2020007233. Blood. 2021. PMID: 33024987 Free PMC article. Clinical Trial.
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Döhner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. DiNardo CD, et al. Among authors: franovic a. J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29. J Clin Oncol. 2021. PMID: 33119479 Free PMC article. Clinical Trial.
The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations.
Balasooriya ER, Wu Q, Ellis H, Zhen Y, Norden BL, Corcoran RB, Mohan A, Martin E, Franovic A, Tyhonas J, Lardy M, Grandinetti KB, Pelham R, Soroceanu L, Silveira VS, Bardeesy N. Balasooriya ER, et al. Among authors: franovic a. Clin Cancer Res. 2024 Mar 4. doi: 10.1158/1078-0432.CCR-23-3588. Online ahead of print. Clin Cancer Res. 2024. PMID: 38437671
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ; CP-MGAH22-5 Study Group. Catenacci DVT, et al. Among authors: franovic a. Lancet Oncol. 2020 Aug;21(8):1066-1076. doi: 10.1016/S1470-2045(20)30326-0. Epub 2020 Jul 9. Lancet Oncol. 2020. PMID: 32653053 Clinical Trial.
A MEK-independent role for CRAF in mitosis and tumor progression.
Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA. Mielgo A, et al. Among authors: franovic a. Nat Med. 2011 Nov 13;17(12):1641-5. doi: 10.1038/nm.2464. Nat Med. 2011. PMID: 22081024 Free PMC article.
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2.
Advani SJ, Camargo MF, Seguin L, Mielgo A, Anand S, Hicks AM, Aguilera J, Franovic A, Weis SM, Cheresh DA. Advani SJ, et al. Among authors: franovic a. Nat Commun. 2015 Sep 3;6:8154. doi: 10.1038/ncomms9154. Nat Commun. 2015. PMID: 26333361 Free PMC article.
MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment.
Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani SJ, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh DA, Anand S. Wilson R, et al. Among authors: franovic a. Nat Commun. 2016 Nov 25;7:13597. doi: 10.1038/ncomms13597. Nat Commun. 2016. PMID: 27886180 Free PMC article.
39 results